Dossier assessment
Epcoritamab (follicular lymphoma, second line or later) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Epcoritamab (follicular lymphoma, second line or later) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Epcoritamab (follicular lymphoma, second line or later) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with relapsed or refractory follicular lymphoma after 1 line of systemic therapy, or after 2 or more lines of systemic therapy
Added benefit not proven
Project details
- Project no.
- A26-84
- Commission
- Commission awarded on 14.07.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
- https://doi.org/10.60584/A26-84
Connected Projects
-
Dossier assessment
Epcoritamab (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Epcoritamab (DLBCL, third line) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed